• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Nektar Therapeutics

Parachute over La Jolla California
Biotech

J&J vet jumps to Affinia—Chutes & Ladders

J&J vet jumps to Affinia. Astellas shakes up C-suite with exec firings. Pfizer builds oncology team with Legos.
Darren Incorvaia , Zoey Becker Feb 7, 2025 8:30am
honey jars

Nektar CEO slams Lilly's 'egregious error,' laments lost time

Aug 8, 2023 8:18pm
Nektar Therapeutics

Nektar accuses Lilly of botching eczema clinical trial analysis

Aug 7, 2023 8:30am
bee flying away bee nectar flower pollen plant lilac

Lilly hands rights to immunology med back to Nektar

Apr 27, 2023 9:14am
Nektar Therapeutics

Nektar sticks with immunology, lays off 60% of SF workforce

Apr 18, 2023 7:00am
Nektar Therapeutics

Lilly, Nektar stop lupus R&D, reassess eczema after phase 2 fail

Feb 24, 2023 6:52am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings